COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response (AMELIORATE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01530711
Recruitment Status : Unknown
Verified August 2016 by Pere Gines, Hospital Clinic of Barcelona.
Recruitment status was:  Active, not recruiting
First Posted : February 10, 2012
Last Update Posted : August 18, 2016
Information provided by (Responsible Party):
Pere Gines, Hospital Clinic of Barcelona

Brief Summary:
Observe the effect of terlipressin on renal function in patients with SHR type I adjusting the dose based on hemodynamic response.

Condition or disease Intervention/treatment Phase
Cirrhosis Hepatorenal Syndrome Type I Drug: Terlipressin and albumin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response
Study Start Date : April 2012
Estimated Primary Completion Date : December 2016
Estimated Study Completion Date : December 2016

Arm Intervention/treatment
Experimental: terlipressin Drug: Terlipressin and albumin

Terlipressin dose: 2mg/24h, it will be modified depending on: Arterial pressure increase < 10 mmHg and the creatinine values decrease <25%, it will be increased every 8 hours until reaching an increase of at least 10mmHg arterial pressure or a creatinine decrease of the 25%.

Albumin: Initial dose (first day) of 1g/Kg (up to a maximum of 100g) and the following days from 20 to 40 g/day.

Primary Outcome Measures :
  1. Changes in arterial pressure and creatinine [ Time Frame: 4 months ]

Secondary Outcome Measures :
  1. Changes in plasmatic renin activity and aldosterone and noradrenaline concentration. [ Time Frame: 4 months ]
  2. Treatment-related adverse events [ Time Frame: 4 months ]
  3. Hepatorenal Syndrome reversion due to hemodynamic changes. [ Time Frame: 4 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with hepatorenal syndrome type 1.
  • Signed informed consent.
  • No exclusion criteria.
  • At least 18 years old
  • Negative pregnancy test in serum or urine in women of childbearing age, and agree to use adequate contraception since at least 14 days prior to the first dose of study drug until 14 days after the last.

Exclusion Criteria:

  • Hepatocellular carcinoma: exclusion of patients with hepatocellular carcinoma who present more than 3 nodules, single nodule larger than 5 cm, tumor portal thrombosis or extrahepatic tumor spread.
  • Active bacterial infection with symptoms of systemic inflammatory response (fever, tachycardia, tachypnea, hypotension, septic or blood count).
  • Cardiac or respiratory failure clinically significant.
  • Clinically significant peripheral artery disease.
  • A history of ischemic heart disease.
  • Hypersensitivity to terlipressin and / or albumin or any of the excipients.
  • Pregnancy.
  • Septic shock.
  • Chronic renal failure.
  • Women in lactation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01530711

Layout table for location information
Corporació Sanitària Parc Taulí
Sabadell, Barcelona, Spain, 08208
Hospital Moisés Broggi
Sant Joan Despí, Barcelona, Spain, 08970
Hospital Clinic i Provincial de Barcelona
Barcelona, Spain, 08036
Hospital del Mar
Barcelona, Spain, 08036
Hospital Vall d´Hebron
Barcelona, Spain, 08036
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain, 08041
Sponsors and Collaborators
Pere Gines
Layout table for investigator information
Principal Investigator: German Soriano Pastor, MD
Principal Investigator: Juan Cordoba, MD
Principal Investigator: Isabel Cirera Lorenzo, MD
Principal Investigator: Marta Martín Llahí, MD
Principal Investigator: Jordi Sánchez Delgado, MD
Layout table for additonal information
Responsible Party: Pere Gines, MD, PhD, Hospital Clinic of Barcelona Identifier: NCT01530711    
Other Study ID Numbers: AMELIORATE
First Posted: February 10, 2012    Key Record Dates
Last Update Posted: August 18, 2016
Last Verified: August 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatorenal Syndrome
Pathologic Processes
Liver Diseases
Digestive System Diseases
Kidney Diseases
Urologic Diseases
Antihypertensive Agents
Vasoconstrictor Agents